Fortanix Introduces New Data Sovereignty Solutions To Help Organizations Meet Evolving Global Data Security and Privacy Requirements
10.10.2023 10:00:00 EEST | Business Wire | Press release
Fortanix® Inc., the data security company and pioneer of Confidential Computing, today announced new capabilities for Fortanix Data Security Manager (DSM) to help public and private organizations address growing data sovereignty requirements globally. Available now, the existing and new features deliver several key capabilities, including support for sovereign cloud, storing keys in sovereign boundaries, anonymization of private data, centralized control to manage access and enforce consistent policies across hybrid and multicloud environments, and more, all delivered via an intuitive user experience.
Organizations around the globe are taking urgent steps to meet strict, complex, and changing data sovereignty regulations. According to a Gartner® report, “Particularly in Europe, but also in other regions, governments are becoming increasingly concerned due to tightening privacy and data protection regulations impacting data sovereignty, data control, technological sovereignty and their dependence on foreign cloud infrastructure providers.”*
Complying with multitude of mandates is a major challenge for organizations, but Fortanix makes it easy for them to ensure compliance over sensitive data, while also bolstering security. The Fortanix flagship DSM offering can be provisioned within customers’ sovereign regions, enabling them to have a dedicated solution that meets regulations in their legislative jurisdictions.
“Data sovereignty goes beyond just where data resides; it is a multi-layered approach that encompasses data security, protection, and privacy. Fortanix’s existing and new capabilities exemplify our commitment to expanding and enhancing DSM to deliver the most advanced data security and privacy solution to organizations around the globe,” said Faiyaz Shahpurwala, chief product and strategy officer at Fortanix. “Security and data teams can now maintain greater international and cross-border security, compliance, and control over their data with a unified platform that is powered by confidential computing and validated by the highest industry certifications.”
“Data sovereignty, data privacy and compliance with regulations such as GDPR and Schrems II are an integral part of our work in behavioral research,” said Raj Jagesar, project lead for the Digital Phenotyping Research Program (Behapp) at the University of Groningen in the Netherlands. “With Fortanix DSM's External Key Manager for Google Cloud, we have full control over our encryption keys not just for compliance purposes, but also to mitigate any security risks related to sensitive personal data.”
Fortanix DSM’s key data sovereignty capabilities include:
- Full control over key generation and lifecycle management for hybrid, multicloud environments with natively integrated KMS and FIPS 140-2 Level 3 HSM
- The ability to store encryption keys separate from data and within sovereign regions
- Enforced least privileged data access with RBAC and Quorum Controls to support Zero Trust architecture
- Crypto agility with rapid migration to latest approved quantum-proof cryptographic algorithms
- Format-preserving encryption to anonymize sensitive data at ingestion or creation before sharing across pipelines and workflows to keep it private, usable, and compliant
- Native database encryption to manage and store the keys required to encrypt all databases, including Oracle, SQL Server, MongoDB, PostGres, MySQL, Maria DB, IBM DB2, and more
- Joint VMware and Fortanix solution for scalable data protection and compliance for VMware Sovereign cloud environments
- Sovereign support for Google Cloud services/offerings in the Kingdom of Saudi Arabia, in partnership with SITE and CNTXT
- Confidential data search, enabling users to quickly search for regulated data in encrypted databases at terabyte scale
- Customer choice of deployment models: on-premises, virtual appliances running in private or public cloud, or a fully managed SaaS across multiple global regions
Fortanix Expands Client-Side Encryption to Gmail
Fortanix has added support for client-side encryption of Gmail messages, rounding out its offering as an external key manager for organizations working in the Google Workspace ecosystem. This means that data will never be sent from a knowledge worker end point such as an employee laptop without it being encrypted while in transit, boosting data privacy and security across the organization.
Fortanix now offers key management for all Google Workspace applications that use client-side encryption, including Docs, Sheets, Calendar, and now Gmail. This enables Fortanix customers who use Google Workspace to create, store, and manage encryption keys themselves, and not through Google.
Meet with Fortanix at it-sa Expo&Congress 2023
Fortanix will once again have a presence at it-sa Expo&Congress 2023, Europe's largest trade event for IT security. The event takes place Oct. 10-12 at Exhibition Centre Nuremberg in Nuremberg, Germany. Fortanix team members will be on hand in Hall 7, booth number 7-627.
For more information and to purchase tickets, visit the it-sa Expo&Congress website.
Additional Resources
- Download the Fortanix Data Security Manager brief
- Read about Fortanix client-side encryption for Google Workspace
- Explore the programming for it-sa Expo&Congress 2023
About Fortanix
Fortanix secures data, wherever it is. Fortanix’s data-first approach helps businesses of all sizes to modernize their security solutions on-premises, in the cloud, and everywhere in between. Enterprises worldwide, especially in privacy-sensitive industries like healthcare, fintech, financial services, government, and retail, trust Fortanix for data security, privacy and compliance. Fortanix investors include Goldman Sachs, Foundation Capital, Intel Capital, In-Q-Tel, Neotribe Ventures and GiantLeap Capital. Fortanix is headquartered in Santa Clara, CA. For more information, visit https://www.fortanix.com.
*Gartner, What Are the Different Provider Approaches to ‘Sovereign Cloud’ Demands?, Rene Buest, Gregor Petri, Neville Cannon, Bart Willemsen, 4 April 2022
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231010355406/en/
Contact information
BOCA Communications for Fortanix
Fortanix@bocacommunications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
